<DOC>
	<DOCNO>NCT02775110</DOCNO>
	<brief_summary>This study evaluate discontinuation natalizumab either immediately tapered treatment multiple sclerosis . Half fifty ( 50 ) participant discontinue natalizumab immediately half taper drug , two additional infusion , one six weeks- one eight weeks-post discontinuation .</brief_summary>
	<brief_title>Natalizumab Temporary Discontinuation Study</brief_title>
	<detailed_description>Natalizumab pharmaceutical intervention use management multiple sclerosis . The decision discontinue natalizumab therapy often raise patient define high-risk PML despite good clinical efficacy . During therapy cessation period follow large phase III trial , return prestudy disease activity reach four month post-discontinuation . Shorter therapy associate trend severe disease activity point possible 'rebound ' effect natalizumab discontinuation . This study focus two different approach : immediate versus step-wise/tapered natalizumab discontinuation protocol , reinstitution different disease modify therapy ( DMT ) within 1-6 month last natalizumab infusion .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Patient relapsingremitting relapsingprogressive ( relapsingremitting incomplete recovery secondary progressive superimpose relapse ) MS accord McDonald criterion natalizumab therapy least 12 month Age 1865 Have EDSS score less equal 7.0 Positive John Cunningham ( JC ) virus antibody result screen Signed inform consent None exclusion criterion Patients willing able personally provide informed consent ( subject cognitive impairment effect ability provide inform consent participation ) Patients active disease per clinical MRI evaluation baseline Patients renal disease precludes MRI gadolinium contrast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>